Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in juvenile dermatomyositis
IRCT20231119060108N1Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in juvenile dermatomyositis (JDM), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Disease activity status, Improvement of clinical symptoms and 2 more. Started Jan 2024; status: completed.
02
Drugs
rituximab
03
Conditions
juvenile dermatomyositis (JDM)
Beyond the preview
Go deeper on IRCT20231119060108N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231119060108N1.